Programme & speakers
Day 1 - Tuesday 27th June 2017
08.45 Registration & welcome coffee
09.15 - 09.30 Welcome Address
09.15 - 09.30 Welcome Address
09.30 - 11.00 Keynote Session I: ADCs, Empowering Cancer Therapy
Chairperson: Nicolas Joubert, Université de Tours
Antibody-Drug Conjugates for Cancer: Current Progress and Future Prospects.
Ravi Chari, Ph.D. - Vice President, Chemistry & Biochemistry, Distinguished Research fellow – Immunogen
Advancement in Antibody Drug Conjugates: A Step Closer to Magic Bullets in War against Cancer
• Advancement in ADCs unleashing a strong clinical pipeline of very promising anticancer drugs
• Five Rights of ADCs, meeting the challenges of off-target toxicities
• Translational approaches to ADC development
Rakesh Dixit, Ph.D., DABT - Vice President R & D, Global Head, Biologics Safety Assessment – MedImmune Inc.
Antibody-Drug Conjugates for Cancer: Current Progress and Future Prospects.
Ravi Chari, Ph.D. - Vice President, Chemistry & Biochemistry, Distinguished Research fellow – Immunogen
Advancement in Antibody Drug Conjugates: A Step Closer to Magic Bullets in War against Cancer• Advancement in ADCs unleashing a strong clinical pipeline of very promising anticancer drugs
• Five Rights of ADCs, meeting the challenges of off-target toxicities
• Translational approaches to ADC development
Rakesh Dixit, Ph.D., DABT - Vice President R & D, Global Head, Biologics Safety Assessment – MedImmune Inc.
11.00 - 11.30 Coffee Break and Poster Session - Partnering (B2B meetings)
11.30 - 12.15 Session II – part 1: Discovery of Novel ADCs Targets and Formats
Chairperson: Maxime Lampilas, Sanofi
Anthracycline-based ADCs :
Anthracycline-based antibody drug conjugates with potent immune-stimulatory functions
Roger Beerli, Ph.D. – Chief Scientific Officer – NBE Therapeutics
Sponsored presentation
Tissue Screen : the tissue based approach to target relevant protein
Renaud Burrer – R&D Manager -
Anthracycline-based ADCs :
Anthracycline-based antibody drug conjugates with potent immune-stimulatory functions
Roger Beerli, Ph.D. – Chief Scientific Officer – NBE Therapeutics
Sponsored presentationTissue Screen : the tissue based approach to target relevant protein
Renaud Burrer – R&D Manager -
12.15 - 13.30 Lunch and Poster Session - Partnering (B2B meetings)
13.30 - 15.00 Session II – part 2: Discovery of Novel ADCs Targets and Formats
An auristatin-based anti-HER3 ADC enhances the efficacy of radiation therapy in pancreatic cancer
Thierry Chardès, Pharm. D., Ph.D. - CNRS Research Director – Research Institute of Cancerology in Montpellier - LabEx MabImprove
Small is Beautiful – Humabody® Drug Conjugates, HDCs a Real Alternative to ADCs
Thomas Sandal - Vice President R&D – Crescendo Biologics
The two faces of interleukin-2; engineering towards applications in oncology and autoimmune diseases
Ekkehard Moessner, Ph.D. - Head of Protein Engineering - Roche Innovation Center, Large Molecules Research
15.00 - 15.30 Coffee Break and Poster Session - Partnering (B2B meetings)
15.30 - 18.30 Pitch Session - New ADC Formats: Diagnostic and Immunomonitoring
Chairpersons: Andreas Pahl, Heidelberg Pharma - Saïd El Alaoui, Covalab
Pitch # 1 :
Gokhan YAHIOGLU – Antikor Biopharma
Not too big - Not too small : Fragment Drug Conjugates (FDCs) as alternatives to ADCS for solid tumors
Pitch # 2 :
Mathieu CINIER – Affilogic
Nanofitins as a versatile platform for cancer imaging and drug conjugates
Pitch # 3 :
Bruno TILLIER - Synthelis
Cell-free expression as an innovative tool for antigen production
Pitch # 4 :
Jonathan SJÖGREN – Genovis
The novel site specific ADC technology GlyCLICK preserves immunoreactivity and allows quantitative conjugation of functional groups to antibody Fc-glycans
Pitch # 5 :
David BONNAFOUS – McSAF
New linker technologies of ADC & bioconjugates developments
Pitch # 6 :
Jean VIALLET – Inovotion
INOVOTION Tests for drug discovery: Early identification of low value ADC
Gokhan YAHIOGLU – Antikor Biopharma
Not too big - Not too small : Fragment Drug Conjugates (FDCs) as alternatives to ADCS for solid tumors
Pitch # 2 :
Mathieu CINIER – Affilogic
Nanofitins as a versatile platform for cancer imaging and drug conjugates
Pitch # 3 :
Bruno TILLIER - Synthelis
Cell-free expression as an innovative tool for antigen production
Pitch # 4 :
Jonathan SJÖGREN – Genovis
The novel site specific ADC technology GlyCLICK preserves immunoreactivity and allows quantitative conjugation of functional groups to antibody Fc-glycans
Pitch # 5 :
David BONNAFOUS – McSAF
New linker technologies of ADC & bioconjugates developments
Pitch # 6 :
Jean VIALLET – Inovotion
INOVOTION Tests for drug discovery: Early identification of low value ADC
Pitch # 7 :
Thibault JONCKHEERE - ImmunXperts
Early Immunogenicity and Immunotoxicity Assessment and Risk Management for ADCs
Pitch # 8 :
Oreda BOUSSADIA – Epivax
The ISPRI Toolkit Rapidly Screens ADC Candidates for Immunogenic Potential Driven by T cell Epitope Content and Foreignness
Pitch # 9 :
Serge DESMOULINS – Agilent
Drug-to-antibody ratio determination for ADCs in serum enabled by a sample preparation platform that automates affinity purification and deglycosylation
Pitch # 10 :
Lisa RECNIK – ICRM-IBMM
Development of an Antibody Radiolabeled Drug Conjugate (ARDC) using 195mPt-Carboplatin for Theranostic Approach in Ovarian Cancer
Pitch # 11 :
Jean-Marc JOUMIER – EasyChelators
C-functionalized Cyclam derivatives as bifunctional chelating agent (BCA) analogues of TETA, TE2A and CB-TE2A
Thibault JONCKHEERE - ImmunXperts
Early Immunogenicity and Immunotoxicity Assessment and Risk Management for ADCs
Pitch # 8 :
Oreda BOUSSADIA – Epivax
The ISPRI Toolkit Rapidly Screens ADC Candidates for Immunogenic Potential Driven by T cell Epitope Content and Foreignness
Pitch # 9 :
Serge DESMOULINS – Agilent
Drug-to-antibody ratio determination for ADCs in serum enabled by a sample preparation platform that automates affinity purification and deglycosylation
Pitch # 10 :
Lisa RECNIK – ICRM-IBMM
Development of an Antibody Radiolabeled Drug Conjugate (ARDC) using 195mPt-Carboplatin for Theranostic Approach in Ovarian Cancer
Pitch # 11 :
Jean-Marc JOUMIER – EasyChelators
C-functionalized Cyclam derivatives as bifunctional chelating agent (BCA) analogues of TETA, TE2A and CB-TE2A
18.30 End of Day 1
20.00 Gala Dinner
20.00 Gala Dinner
Day 2 - Wednesday 28th June 2017
08.15 Registration & welcome coffee
08.30 - 10.30 Session III – Accelerate the Development of the Next-Generation ADCs
Chairperson: Alain Beck, Centre d'Immunologie Pierre Fabre
CovIsoLinkTM: New bacterial transglutaminase Q-tag substrate for the development of site specific Antibody Drug Conjugates
Saïd El Alaoui, Ph.D. – Chief Executive Officer - Covalab
Enzymatic site specific conjugation using transglutaminase to obtain homogeneous ADC
François Romagné, Ph.D. – Scientific Director – MI-mAbs
Amanitin-based Antibody-Drug-Conjugates as New Therapeutic Modalities for Cancer Therapy
Andreas Pahl, Prof. Dr. – Chief Scientific Officer – Heidelberg Pharma
Development of new cryptophycins as promising tubulin binder payloads for ADCs
Marie-Priscille Brun, Ph.D. – Immunoconjugate Leader / Chemical biology group – Sanofi
CovIsoLinkTM: New bacterial transglutaminase Q-tag substrate for the development of site specific Antibody Drug Conjugates
Saïd El Alaoui, Ph.D. – Chief Executive Officer - Covalab
Enzymatic site specific conjugation using transglutaminase to obtain homogeneous ADC
François Romagné, Ph.D. – Scientific Director – MI-mAbs
Amanitin-based Antibody-Drug-Conjugates as New Therapeutic Modalities for Cancer TherapyAndreas Pahl, Prof. Dr. – Chief Scientific Officer – Heidelberg Pharma
Development of new cryptophycins as promising tubulin binder payloads for ADCs
Marie-Priscille Brun, Ph.D. – Immunoconjugate Leader / Chemical biology group – Sanofi
10.30 - 11.00 Coffee Break and Poster Session - Partnering (B2B meetings)
11.00 - 12.30 Session IV – Challenges in ADC developability, scale-up and manufacturing
Chairperson: François Romagné, MI-mAbs
Keynote presentation
Insights of multilevel state-of-the art analytical methods for ADCs structural assessment
Alain Beck, PhD - Senior Director, Analytical Chemistry, New Biological Entities - Centre d'Immunologie Pierre Fabre - Associate Editor of mAbs journal
Sponsored presentation
ADC Easy Access : From the Lab to the Clinic
Régis Lelou - Senior Bioengineer – R&D Chemicals
Sponsored presentation
Integrated services for immuno-conjugate development and production:
Symbiotic combination of R&D expertise and industrial leadership for successful development of mAbs
Eric Devic, Ph. D. – Founder-President and COO – GTP Technology
Novasep's integrated solutions for ADC
François D’Hooge, Ph.D. - Head of Bioconjugation Unit – Novasep
Need for speed – how to accelerate the development of an ADC
Klaus Kaiser - Head of Downstream – Bayer
Keynote presentationInsights of multilevel state-of-the art analytical methods for ADCs structural assessment
Alain Beck, PhD - Senior Director, Analytical Chemistry, New Biological Entities - Centre d'Immunologie Pierre Fabre - Associate Editor of mAbs journal
Sponsored presentationADC Easy Access : From the Lab to the Clinic
Régis Lelou - Senior Bioengineer – R&D Chemicals
Sponsored presentationIntegrated services for immuno-conjugate development and production:
Symbiotic combination of R&D expertise and industrial leadership for successful development of mAbs
Eric Devic, Ph. D. – Founder-President and COO – GTP Technology
Novasep's integrated solutions for ADC
François D’Hooge, Ph.D. - Head of Bioconjugation Unit – Novasep
Need for speed – how to accelerate the development of an ADC
Klaus Kaiser - Head of Downstream – Bayer
12.30 - 14.00 Lunch and Poster Session - Partnering (B2B meetings)
14.00 - 16.00 Session V - Moving ADCs Forward Into the Clinic: Safety and Efficacy
Chairperson: François Lefoulon, Servier
Update on PBDs
Philip Howard, Ph.D. – CSO, Senior Fellow - Spirogen
Mechanisms of resistance to ADCs
Charles Dumontet, Prof. Ph.D - Senior Physician in Hematology – Hospices civils de Lyon
Clinical pharmacology of ADCs
Gilles Paintaud, PU-PH – Head of CNRS UMR 7292 – University of Tours - LabEx MabImprove
ADC Safety & Toxicity: Technology Choices and Importance of Process Development to Control Safety related CQAs
Olivier Marcq, Ph.D. – Group leader Development and Manufacturing – Agensys
Update on PBDs
Philip Howard, Ph.D. – CSO, Senior Fellow - Spirogen
Mechanisms of resistance to ADCs
Charles Dumontet, Prof. Ph.D - Senior Physician in Hematology – Hospices civils de Lyon
Clinical pharmacology of ADCs
Gilles Paintaud, PU-PH – Head of CNRS UMR 7292 – University of Tours - LabEx MabImprove
ADC Safety & Toxicity: Technology Choices and Importance of Process Development to Control Safety related CQAs
Olivier Marcq, Ph.D. – Group leader Development and Manufacturing – Agensys
16.00 - 17.00 Outsourcing roundtable: mAbs and ADCs outsourcing, opportunities and challenges - Partnering (B2B meetings)
Chairperson: Florence Lhospice, Innate Pharma
Arnaud Martin, Director CMO Business - Sanofi
Régis Lelou, Senior Bioengineer – R&D Chemicals - Lonza
Christophe Aussourd, Planning and Supply Director - Servier
Arnaud Martin, Director CMO Business - Sanofi
Régis Lelou, Senior Bioengineer – R&D Chemicals - Lonza
Christophe Aussourd, Planning and Supply Director - Servier
17.00 - 17.30 Closing Remarks, Announcement of the AIS2018
17.30 End of Symposium